Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study
Latest Information Update: 28 Sep 2022
At a glance
- Drugs Camrelizumab (Primary) ; Cisplatin (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
- 22 Sep 2022 Status changed from not yet recruiting to recruiting.
- 10 Aug 2022 New trial record